¼¼°èÀÇ ÃéÀå¾Ï Áø´Ü ½ÃÀå
Pancreatic Cancer Diagnostic
»óǰÄÚµå : 1775046
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 469 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ÃéÀå¾Ï Áø´Ü ½ÃÀåÀº 2030³â±îÁö 36¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 26¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÃéÀå¾Ï Áø´Ü ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 5.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 36¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÃéÀå¾Ï Áø´Ü ¼Ò¸ðǰÀº º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀ̸ç, CAGRÀº 6.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 21¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÃéÀå¾Ï Áø´Ü ÀåÄ¡ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 1,060¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÃéÀå¾Ï Áø´Ü ½ÃÀåÀº 2024³â¿¡ 7¾ï 1,060¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 8.8%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 7¾ï 2,620¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.5%¿Í 5.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÃéÀå¾Ï Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö ÃéÀå¾Ï Áø´Ü¾àÀÌ ÇコÄɾîÀÇ ¿ì¼±¼øÀ§·Î ¼ºÀåÇϰí Àִ°¡?

ÃéÀå¾Ï Áø´Ü ½ÃÀåÀº °¡Àå °ø°ÝÀûÀÌ°í ¹ß°ßÇϱ⠾î·Á¿î ¾Ç¼º Á¾¾ç Áß ÇϳªÀÎ ÃéÀå¾ÏÀÇ Àü ¼¼°è ¹ßº´·ü Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¸»±â Áø´Ü°ú ³·Àº »ýÁ¸À²·Î ÀÎÇØ Á¶±â¿¡ º¸´Ù Á¤È®ÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿µ»óÁø´Ü, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç, ¾×ü»ý°Ë ±â¼úÀÇ ¹ßÀüÀº Á¶±â ¹ß°ß ´É·ÂÀ» Å©°Ô Çâ»ó½ÃÄÑ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ³ëÀÎ Àα¸ Áõ°¡¿Í ÃéÀå¾ÏÀÇ À¯ÀüÀû ¼ÒÀο¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ °ËÁø ÇÁ·Î±×·¥ ¹× Áø´Ü Çõ½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Ï ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀçÁ¤ Áö¿ø°ú ¹Î°£ ÅõÀÚ·Î ÀÎÇØ ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¾×ü»ý°Ë°ú AI ±â¹Ý Áø´ÜÀÌ °ËÁøÀ» ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡?

¾×ü»ý°Ë ±â¼úÀº ¼øÈ¯ Á¾¾ç DNA(ctDNA)¿Í ¿¢¼ÒÁ» ¸¶Ä¿¸¦ ºñħ½ÀÀûÀ¸·Î °ËÃâÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ÃéÀå¾Ï Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¾×ü»ý°ËÀº Á¶±â Áø´Ü, ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ¸ÂÃãÇü Ä¡·á °èȹÀÇ °¡´É¼ºÀ» Á¦°øÇϰí, ħ½ÀÀû »ý°Ë¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·ÃçÁÝ´Ï´Ù.

AI¸¦ Ȱ¿ëÇÑ ¿µ»ó Áø´Ü ¹× ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº CT ½ºÄµ, MRI µ¥ÀÌÅÍ, º´¸® Á¶Á÷ ½½¶óÀ̵带 º¸´Ù È¿À²ÀûÀ¸·Î ºÐ¼®ÇÏ¿© Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í ÀÖÀ¸¸ç, AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ¸ðµ¨Àº ¿µ»ó µ¥ÀÌÅÍÀÇ ¹Ì¹¦ÇÑ ÆÐÅÏÀ» ÆÄ¾ÇÇÏ¿© ÃéÀå¾ÏÀÇ Á¶±â ¹ß°ß ¹× À§Çèµµ Æò°¡¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á¿Í À¯ÀüÀÚ °Ë»ç´Â ½ÃÀå ±âȸ¸¦ È®´ëÇÒ °ÍÀΰ¡?

BRCA1, BRCA2 ¹× ±âŸ À¯ÀüÀû µ¹¿¬º¯ÀÌ À¯ÀüÀÚ °Ë»ç´Â °íÀ§Ç豺À» ½Äº°ÇÏ¿© ¿¹¹æÀû ½ºÅ©¸®´× ¹× °³Àκ° ¸ÂÃã Ä¡·á Àü·«À» °¡´ÉÇÏ°Ô Çϰí, PARP ¾ïÁ¦Á¦ ¹× ¸é¿ª ¿ä¹ý°ú °°Àº Ç¥Àû Ä¡·áÁ¦¿Í ¿¬°èµÈ µ¿¹Ý Áø´ÜÀº °í±Þ ºÐÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·áÁ¦¿Í ¿¬°èµÈ µ¿¹Ý Áø´Ü ¾àǰÀº °í±Þ ºÐÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐÀ» °áÇÕÇÑ ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀº Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ã۰í, º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃãÈ­µÈ Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖ´Â ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ÷´Ü ÃéÀå¾Ï Áø´Ü¾à¿¡ ´ëÇÑ ¼ö¿ä´Â ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÃéÀå¾Ï Áø´ÜÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÃéÀå¾Ï Áø´Ü¾à ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ À¯º´·ü Áõ°¡, ¾×ü»ý°Ë ¹× AI¸¦ Ȱ¿ëÇÑ ¿µ»óÁø´ÜÀÇ ¹ßÀü, Á¶±â ¹ß°ß¿¡ ÀÖ¾î À¯ÀüÀÚ °Ë»çÀÇ ¿ªÇÒ È®´ë¿¡ ±âÀÎÇÕ´Ï´Ù. Á¤¹ÐÀÇ·á¿Í µ¿¹ÝÁø´ÜÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå Æ®·»µå¸¦ ´õ¿í Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Çõ½ÅÀûÀÎ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß°ú ÇÔ²² ¾Ï ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ºÎ¹®ÀÇ ÅõÀÚ°¡ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. »ýÁ¸À² Çâ»óÀ» À§Çؼ­´Â Á¶±â ¹ß°ßÀÌ ÇʼöÀûÀ̱⠶§¹®¿¡ ÃéÀå¾Ï Áø´ÜÁ¦ ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÃéÀå¾Ï Áø´Ü ¼Ò¸ðǰ, ÃéÀå¾Ï Áø´Ü ÃøÁ¤±â, ÃéÀå¾Ï Áø´Ü ¼­ºñ½º);°Ë»ç À¯Çü(¿µ»ó °Ë»ç, »ý°Ë °Ë»ç, Ç÷¾×°Ë»ç, ±âŸ °Ë»ç À¯Çü);¾Ï À¯Çü(¿ÜºÐºñ¾Ï, ³»ºÐºñ ¾Ï);ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿¬±¸½Ç ÃÖÁ¾»ç¿ëÀÚ, Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pancreatic Cancer Diagnostic Market to Reach US$3.6 Billion by 2030

The global market for Pancreatic Cancer Diagnostic estimated at US$2.6 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Pancreatic Cancer Diagnostic Consumables, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Pancreatic Cancer Diagnostic Instruments segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$710.6 Million While China is Forecast to Grow at 8.8% CAGR

The Pancreatic Cancer Diagnostic market in the U.S. is estimated at US$710.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$726.2 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Pancreatic Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is Pancreatic Cancer Diagnostics a Growing Healthcare Priority?

The pancreatic cancer diagnostics market is expanding rapidly due to the increasing global incidence of pancreatic cancer, one of the most aggressive and difficult-to-detect malignancies. Late-stage diagnoses and poor survival rates have intensified the need for early and more accurate diagnostic solutions. Advancements in imaging, biomarker testing, and liquid biopsy technologies are significantly improving early detection capabilities, leading to better patient outcomes.

Additionally, the rising geriatric population and growing awareness of genetic predisposition to pancreatic cancer are driving demand for screening programs and diagnostic innovations. Government funding and private investments in cancer research are further accelerating market expansion.

How Are Liquid Biopsy and AI-Driven Diagnostics Transforming Detection?

The adoption of liquid biopsy techniques is revolutionizing pancreatic cancer diagnostics by enabling non-invasive detection of circulating tumor DNA (ctDNA) and exosomal markers. Liquid biopsy offers the potential for earlier diagnosis, real-time monitoring, and personalized treatment planning, reducing reliance on invasive biopsy procedures.

AI-powered imaging and machine learning algorithms are also enhancing diagnostic accuracy by analyzing CT scans, MRI data, and histopathology slides more efficiently. AI-driven predictive models are identifying subtle patterns in imaging data, aiding early-stage pancreatic cancer detection and risk assessment.

Is Precision Medicine and Genetic Testing Expanding Market Opportunities?

The integration of precision medicine into pancreatic cancer diagnostics is expanding market opportunities. Genetic testing for BRCA1, BRCA2, and other hereditary mutations is helping identify individuals at high risk, enabling proactive screening and personalized treatment strategies. Companion diagnostics linked to targeted therapies, such as PARP inhibitors and immunotherapies, are further driving demand for advanced molecular testing.

Additionally, multi-omic approaches that combine genomics, proteomics, and metabolomics are improving diagnostic accuracy, paving the way for more effective and tailored treatment plans. As personalized medicine continues to evolve, demand for advanced pancreatic cancer diagnostics is expected to rise.

What’s Driving the Growth of the Pancreatic Cancer Diagnostics Market?

The growth in the pancreatic cancer diagnostics market is driven by increasing disease prevalence, advancements in liquid biopsy and AI-powered imaging, and the expanding role of genetic testing in early detection. The rising adoption of precision medicine and companion diagnostics is further shaping market trends.

Additionally, government and private sector investments in cancer research, coupled with the development of innovative diagnostic biomarkers, are fueling market expansion. As early detection remains critical in improving survival rates, the pancreatic cancer diagnostics market is poised for continued growth.

SCOPE OF STUDY:

The report analyzes the Pancreatic Cancer Diagnostic market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Pancreatic Cancer Diagnostic Consumables, Pancreatic Cancer Diagnostic Instruments, Pancreatic Cancer Diagnostic Services); Test Type (Imaging Test, Biopsy Test, Blood Test, Other Test Types); Cancer Type (Exocrine Cancer, Endocrine Cancer); End-Use (Hospitals End-Use, Laboratories End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â